Literature DB >> 10548150

Does exercise radionuclide angiography still have a role in clinical cardiac assessment?

A D Kelion, A P Banning, O J Ormerod.   

Abstract

Mesh:

Year:  1999        PMID: 10548150     DOI: 10.1016/s1071-3581(99)90027-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  40 in total

1.  Sensitivity, specificity and predictive accuracy of radionuclide cineangiography during exercise in patients with coronary artery disease. Comparison with exercise electrocardiography.

Authors:  J S Borer; K M Kent; S L Bacharach; M V Green; D R Rosing; S F Seides; S E Epstein; G S Johnston
Journal:  Circulation       Date:  1979-09       Impact factor: 29.690

2.  Incremental value of simultaneous assessment of myocardial function and perfusion with technetium-99m sestamibi for prediction of extent of coronary artery disease.

Authors:  W Palmas; J D Friedman; G A Diamond; H Silber; H Kiat; D S Berman
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

3.  Prognostic indicators from radionuclide angiography in medically treated patients with coronary artery disease.

Authors:  D B Pryor; F E Harrell; K L Lee; R A Rosati; R E Coleman; F R Cobb; R M Califf; R H Jones
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

4.  Cardiac imaging for risk stratification with dobutamine-atropine stress testing in patients with chest pain. Echocardiography, perfusion scintigraphy, or both?

Authors:  M L Geleijnse; A Elhendy; R T van Domburg; J H Cornel; R Rambaldi; A Salustri; A E Reijs; J R Roelandt; P M Fioretti
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

5.  Prediction of death and myocardial infarction by radionuclide angiocardiography in patients with suspected coronary artery disease.

Authors:  S H Johnson; C Bigelow; K L Lee; D B Pryor; R H Jones
Journal:  Am J Cardiol       Date:  1991-05-01       Impact factor: 2.778

6.  Prognosis by measurements of left ventricular function during exercise. Duke Noninvasive Research Working Group.

Authors:  L J Shaw; S K Heinle; S Borges-Neto; K Kesler; R E Coleman; R H Jones
Journal:  J Nucl Med       Date:  1998-01       Impact factor: 10.057

7.  Dipyridamole radionuclide ventriculography: a test with high specificity for severe coronary artery disease.

Authors:  C U Cates; M W Kronenberg; H W Collins; M P Sandler
Journal:  J Am Coll Cardiol       Date:  1989-03-15       Impact factor: 24.094

8.  Effects of beta-adrenergic blocking drugs on sensitivity and specificity of radionuclide ventriculography during exercise in patients with coronary heart disease.

Authors:  J Lindsay; N G Nolan; S A Goldstein; J M Bacos
Journal:  Am Heart J       Date:  1983-08       Impact factor: 4.749

9.  Exercise-induced ischemia in mildly symptomatic patients with coronary-artery disease and preserved left ventricular function. Identification of subgroups at risk of death during medical therapy.

Authors:  R O Bonow; K M Kent; D R Rosing; K K Lan; E Lakatos; J S Borer; S L Bacharach; M V Green; S E Epstein
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

10.  Prognosis in patients with an abnormal exercise radionuclide angiogram in the absence of significant coronary artery disease.

Authors:  T D Miller; C P Taliercio; A R Zinsmeister; R J Gibbons
Journal:  J Am Coll Cardiol       Date:  1988-09       Impact factor: 24.094

View more
  2 in total

1.  Does a selective adenosine A(1) receptor agonist protect against exercise induced ischaemia in patients with coronary artery disease?

Authors:  A D Kelion; T P Webb; M A Gardner; O J Ormerod; G L Shepherd; A P Banning
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Assessment of ejection fraction with Tl-201 gated SPECT in myocardial infarction: Precision in a rest-redistribution study and accuracy versus planar angiography.

Authors:  E Itti; J Rosso; P Damien; M Auffret; J P Thirion; M Meignan
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.